December 10, 2025

The LinkedIn Pharma Power Rankings: Who’s Winning the Conversation in 2025?

Leading pharmaceutical companies are discovering how to align their innovation story with what patients and professionals really want to hear.

When pharma companies share their stories on LinkedIn, they rightfully lead with innovation. When LinkedIn users discuss these same companies, they want to understand access and affordability alongside those breakthroughs.

This isn’t a crisis-it’s an opportunity. Our analysis of 228,100 LinkedIn mentions across 10 pharmaceutical companies reveals a strategic opening: the industry has built tremendous credibility around innovation, and now has the chance to extend that narrative to address the questions their audience is actively asking. This study was conducted by combining mainstream media monitoring and social media listening insights using Onclusive 360 and Onclusive Social.

In an industry where scientific advancement moves at unprecedented speed, the companies that can tell the complete story-from lab to patient-will build lasting competitive advantage.

Key Takeaways about Pharma Companies on LinkedIn

• AstraZeneca leads pharmaceutical owned media activity on LinkedIn with 223 posts in three months, followed by Boehringer Ingelheim (180) and Pfizer (126) 50.30% of pharma content focuses on Innovation & R&D – demonstrating the industry’s commitment to showcasing scientific advancement.
• 28.3% of audience conversations center on Drug Pricing & Access – revealing a 22-percentage-point content-audience gap.
• 26.3% of discussions involve Clinical Trials & Research – showing high audience engagement with scientific content.
• 18.4% of conversations focus on vaccines – indicating sustained public interest in preventive medicine.
• The opportunity: Pharmaceutical companies can extend their strong innovation narrative by proactively addressing access and affordability topics.
• The solution: A balanced content mix that maintains innovation leadership while answering the questions audiences are actively asking.

The Strong Foundation: What Pharma Companies Are Doing Right

Over the last three months, pharmaceutical companies demonstrated good LinkedIn engagement, thanks to their regular and relevant publication, with AstraZeneca leading at 223 posts, followed by Boehringer Ingelheim (180), Pfizer (126), and Bristol-Myers Squibb (122). This consistent, high-quality output shows the industry’s commitment to professional engagement.

Owned Media: What Companies Communicate. Publication by companies. Scope: main LinkedIn accounts of companies. Based on an analysis of 1752 mentions during 3 months.

Innovation Leadership: A Strategic Necessity

50.30% of pharmaceutical companies’ LinkedIn content focuses on Innovation & R&D- and for excellent reasons.

This heavy investment in innovation storytelling makes strategic sense:

• Investor confidence: Demonstrating pipeline strength and future revenue potential.
• Price justification: Connecting high R&D costs to breakthrough therapies.
• Talent attraction: Positioning companies as leaders in cutting-edge science.
• Competitive differentiation: Showcasing unique capabilities and therapeutic advances.

This isn’t misguide, it’s mission-critical. Without innovation, pharmaceutical companies can’t serve patients. The 50% allocation reflects the industry’s core purpose: advancing medical science.

Patient-Centric Progress

Diseases & Therapies content (26%) shows the industry’s evolution toward patient-focused storytelling. Companies are increasingly:

• Humanizing their brands through patient impact stories.
• Raising awareness of underserved disease areas.
• Creating emotional connections beyond products.
• Demonstrating concrete health outcomes.

This shift from “what we make” to “who we help” represents meaningful progress in corporate communication.

Smart Employer Branding

Employment & Careers (3.70%) reflects sophisticated multi-purpose communication. Pharmaceutical companies recognize LinkedIn as both a stakeholder engagement platform and a talent acquisition channel.

In a fierce competition for data scientists, AI specialists, and biotech researchers, these companies are smartly leveraging their innovation narrative for recruitment. This is strategic efficiency, not mission drift.

(* Study conducted over a period of 3 months. The number of posts per company may vary depending on their news and seasonality.)

Want to see how your pharmaceutical company performs on LinkedIn compared to competitors? Download our complete Pharmaceutical Industry Scan 2025 for share of voice rankings, sentiment analysis, and competitive benchmarking across all major platforms.

The Audience Insight: What Stakeholders Are Curious About

Now for the fascinating part: what happens when pharmaceutical companies aren’t controlling the narrative reveals incredible audience engagement opportunities.

The Access Conversation: An Invitation for Leadership

28.3% of earned media conversations about pharma companies focus on Drug Pricing & Access.

Here’s the positive reframe: nearly a third of your audience is actively engaged with healthcare access topics and waiting for pharmaceutical companies to lead this conversation.

This represents enormous opportunity:

• Audience engagement: People care deeply about these issues and want to understand them.
• Thought leadership space: Relatively few companies are addressing this proactively.
• Trust-building potential: Transparent communication here creates differentiation.
• Policy influence: Educated stakeholders become advocates.

The most popular topic categories on LinkedIn in conversation related to pharmaceutical companies

The conversations happening include:

• Questions about pricing structures (curiosity, not just criticism).
• Interest in patient assistance programs.
• Comparisons that reveal complexity of different healthcare systems.
• Calls for industry innovation in access models.

The key insight: People aren’t rejecting pharmaceutical innovation, they want to understand how that innovation becomes accessible. This is an invitation to complete your story, not abandon it.

Clinical Trials: High Engagement Opportunity

At 26.3%, Clinical Trials & Research ranks remarkably high in earned media, nearly matching company-controlled R&D messaging.

This is phenomenal news. It means:

• Growing health literacy: Audiences want to understand the science.
• Active participation interest: Patients seeking trial opportunities.
• Transparency appetite: Stakeholders engaging with methodology and results.
• Partnership mindset: Communities wanting to contribute to medical advances.

The distinction in conversation types reveals opportunity:

• Company messaging: Pipeline strength, breakthrough potential, scientific leadership.
• User discussions: Practical participation, eligibility questions, real-world outcomes.

Smart pharmaceutical companies can bridge this easily by making trial information more accessible while maintaining scientific rigor.

Vaccines: Sustained Interest Creating Dialogue Opportunities

18.4% of conversations focus on vaccines, demonstrating sustained public interest in preventive medicine.

While sentiment is mixed, this creates valuable opportunities:

• Education platform: High engagement means people want to learn.
• Scientific communication: Chance to explain complex immunology accessibly.
• Public health leadership: Industry expertise in critical health issues.
• Long-term relationship building: Ongoing dialogue rather than one-time transactions.

The diversity of perspectives (pro-vaccine advocacy, safety questions, scientific analysis) indicates an active, engaged audience willing to discuss complex topics- exactly what pharmaceutical companies need for meaningful stakeholder relationships.

The 22-Point Opportunity: Strategic Alignment

Here’s the strategic opportunity:

• Pharmaceutical companies dedicate 50.30% of LinkedIn content to Innovation & R&D.
• LinkedIn users dedicate 28.3% of their pharma discussions to Drug Pricing & Access.

This 22-percentage-point gap represents untapped communication territory where pharmaceutical companies can differentiate themselves, build trust, and complete their innovation narrative.

Why This Opportunity Is Valuable

1. First-Mover Advantage

Few pharmaceutical companies are proactively addressing access and affordability with the same sophistication they bring to innovation messaging. Early movers will establish thought leadership.

2. Complete Brand Story

Innovation without access is incomplete. Companies that connect breakthrough science to patient access tell a more compelling, credible story.

3. Talent Attraction Enhancement

Top professionals, especially younger generations, want to work for companies that demonstrate both scientific excellence and societal impact. Addressing access strengthens employer brand.

4. Stakeholder Trust Building

Transparent communication about complex issues like pricing builds credibility that pays dividends during both routine operations and crisis situations.

Strategic Recommendations: Amplifying What’s Working

1. Extend Your Innovation Story

You’ve built incredible credibility around R&D. Now complete the narrative by connecting innovation to access:

Evolution approach: “We’re developing breakthrough cancer therapies, and here’s how we’re ensuring patients can benefit from them.”

This doesn’t replace innovation messaging; it enhances it by answering the natural follow-up question your audience is already asking.

2. Lead the Access Conversation

Rather than avoiding pricing discussions, lead them proactively:

• Explain R&D costs transparently (you’re already sharing the science).
• Showcase patient assistance programs prominently.
• Share success stories of patients who accessed medications.
• Discuss industry challenges candidly.

This demonstrates confidence and builds trust.

3. Make Trial Content More Accessible

You’re already investing in clinical trials communication. Enhance it by adding:

• Clear, patient-friendly eligibility criteria.
• Participation process explanations.
• Patient testimonials from actual trial participants.
• Transparent results sharing (successes and learnings).

This leverages your existing strength while addressing audience interest.

4. Optimize Content Mix

Consider adjusting your content allocation:

• 40% Innovation & R&D (maintain strength).
• 25% Diseases & Therapies (continue patient focus).
• 20% Access & Affordability (address audience interest).
• 10% Clinical Trials (make practical).
• 5% Other topics.

This maintains your innovation leadership while addressing the full patient journey.

5. Activate Your Greatest Asset: People

Your scientists, clinicians, and patient advocates have tremendous credibility:

• Encourage researchers to explain their work in accessible terms.
• Have patient services teams showcase assistance programs.
• Let employees share why they’re passionate about both science and access.

This humanizes complex topics and builds authentic connections.

The Path Forward: Building on Strong Foundations

Pharmaceutical companies have built remarkable LinkedIn presence around innovation, and rightfully so. This foundation of scientific credibility is invaluable.

The opportunity now is to extend this strength by addressing the questions your engaged audience is actively asking. They’re not rejecting your innovation story; they want to understand the complete journey from breakthrough to bedside.

50.30% innovation. 28.3% pricing interest. 22 points of opportunity.

The companies that will lead aren’t those that abandon their innovation narrative. They’re the ones that complete it by connecting scientific advancement to patient access, making innovation and affordability complementary rather than competing narratives.

This is the next evolution of pharmaceutical leadership: companies confident enough to discuss complexity, transparent enough to acknowledge challenges, and sophisticated enough to tell the complete story of how breakthrough science becomes accessible healthcare.

Conclusion

Your audience is engaged, curious, and asking questions. They’re interested in clinical trials, want to understand pricing, and care about access. This isn’t opposition-it’s an invitation to deeper dialogue.

The pharmaceutical companies that accept this invitation, bringing the same sophistication to access discussions that they bring to innovation storytelling, will build the stakeholder trust that defines industry leadership.